Jana Care has raised $6m in the Series B financing round, to complete the commercialisation of its self-administered blood tests for kidney and heart disease.
The financing round saw participation from both new and existing venture corporations, with IAG Capital Partners becoming the new lead investor that joined the investor syndicate and global strategic partners to support the development of Jana Care's blood testing platform.
Jana Care intends to use the funds for further development of its quantitative blood testing platform.
The platform is intended to facilitate self-administered blood tests at home, enabling clinicians to remotely review the test results as required.
The platform's features are designed to address the challenges of distance and socioeconomic barriers that hinder the timely detection and monitoring of chronic kidney and heart disease progression.
Jana Care CEO Anh Hoang-Lindsay said: “Building on the strength of our global strategic partnerships, we are proud to expand our investor base in our fight to bridge the access gap for many chronic disease patients, especially in these post-pandemic times.”
The pandemic increased the use of telehealth services, leading to improved management of both acute and chronic conditions.
This trend underscores the demand for dependable at-home technologies that offer a convenient solution for measuring vital analytes in remote or challenging-to-access environments while addressing the difficulties of adhering to testing guidelines.
IAG Capital Partners venture partner and the new board of directors member Dr Ehsan Jabbarzadeh said: “We are thrilled to support Jana Care and its mission to increase quality of life for patients with chronic illness and are honoured to support the management team.”
